Alpinia oxyphylla Miq.: Chemical Constituents, Neuroprotective and Metabolic Effects, and Translational Challenges—A Review of Preclinical Evidence
- 1College of Science Yunnan Agricultural University Kunming China
- 2Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education Yunnan Agricultural University Kunming China
- 3College of Food Science and Technology Yunnan Agricultural University Kunming China
Abstract
Alpinia oxyphylla Miq. (AOM), a traditional resource with both medicinal and edible uses, has attracted increasing interest for its reported neuroprotective and metabolic activities. However, its active constituents, molecular mechanisms, and potential applications in functional food development remain incompletely defined. This review consolidates evidence on the major bioactive constituents of AOM, including diphenylheptanoids, polysaccharides, flavonoids, terpenoids, and phenolic acids, and summarizes reported molecular targets and pathways associated with neural and metabolic homeostasis. The available preclinical evidence suggests that AOM and its constituents may affect experimental models of Alzheimer's disease, Parkinson's disease, diabetes, and related complications through modulation of neuroinflammation, oxidative stress, PI3K/Akt‐associated signaling, and the gut microbiota‐metabolite axis. Some AOM‐containing herb‐pair formulations have also shown enhanced effects in preclinical models, and AOM constituents have been associated with anti‐allergic, cardioprotective, and antitumor activities. Finally, this review discusses translational challenges for AOM‐based functional food and nutraceutical development, including bioavailability, quality control, delivery systems, safety, and the scarcity of human clinical evidence. Overall, the current evidence supports AOM as a promising botanical resource for further mechanistic and translational research, while therapeutic and product‐development claims should be interpreted with appropriate caution until supported by robust clinical and safety data.
Related
- Herbal-derived bioactive compounds in stroke recovery: from neuroprotective mechanisms to clinical evidence and translational challenges
- Traditional Chinese Medicine for Diabetic Kidney Disease: Predominantly Preclinical Evidence, Mechanistic Pathways, and Translational Challenges.
- Tanshinone IIA in colorectal cancer: preclinical mechanisms, therapeutic sensitization, and translational prospects
- Optimizing therapeutic hypothermia conditions in a translational preclinical model of neonatal hypoxia-ischemia in rats
- The Translational Value of Preclinical Research: Lessons from More Than Forty Years of Retinal Research
BibTeX
@article{yang2026alpinia,
title = {{Alpinia oxyphylla Miq.: Chemical Constituents, Neuroprotective and Metabolic Effects, and Translational Challenges—A Review of Preclinical Evidence}},
author = {Ziyan Yang and Hemei Yuan and Dengyou Nie and Jun Sheng and Titi Liu and Huanhuan Xu},
journal = {Food science \& nutrition},
year = {2026},
month = nov,
doi = {10.1002/fsn3.72553},
url = {https://europepmc.org/article/PMC/PMC13725049},
note = {CC BY},
}
RIS
TY - JOUR
TI - Alpinia oxyphylla Miq.: Chemical Constituents, Neuroprotective and Metabolic Effects, and Translational Challenges—A Review of Preclinical Evidence
AU - Ziyan Yang
AU - Hemei Yuan
AU - Dengyou Nie
AU - Jun Sheng
AU - Titi Liu
AU - Huanhuan Xu
PY - 2026
DA - 2026/11/01
JO - Food science & nutrition
DO - 10.1002/fsn3.72553
UR - https://europepmc.org/article/PMC/PMC13725049
AB - Alpinia oxyphylla Miq. (AOM), a traditional resource with both medicinal and edible uses, has attracted increasing interest for its reported neuroprotective and metabolic activities. However, its active constituents, molecular mechanisms, and potential applications in functional food development remain incompletely defined. This review consolidates evidence on the major bioactive constituents of AOM, including diphenylheptanoids, polysaccharides, flavonoids, terpenoids, and phenolic acids, and summarizes reported molecular targets and pathways associated with neural and metabolic homeostasis. The available preclinical evidence suggests that AOM and its constituents may affect experimental models of Alzheimer's disease, Parkinson's disease, diabetes, and related complications through modulation of neuroinflammation, oxidative stress, PI3K/Akt‐associated signaling, and the gut microbiota‐metabolite axis. Some AOM‐containing herb‐pair formulations have also shown enhanced effects in preclinical models, and AOM constituents have been associated with anti‐allergic, cardioprotective, and antitumor activities. Finally, this review discusses translational challenges for AOM‐based functional food and nutraceutical development, including bioavailability, quality control, delivery systems, safety, and the scarcity of human clinical evidence. Overall, the current evidence supports AOM as a promising botanical resource for further mechanistic and translational research, while therapeutic and product‐development claims should be interpreted with appropriate caution until supported by robust clinical and safety data.
SN - 2048-7177
ER -